Humana (HUM), the leading health insurance provider, has been faced with numerous ups and downs in recent months. Q3 was marked by notable
volatility, linked to changes in asset management strategies by several institutions, which resulted in the purchase of 4,122 HUM shares by
Oddo BHF Asset Management Sas and the sale of 10,535 HUM shares by
Pine Valley Investments Ltd. HUM's call-put ratio reflected this uncertainty, standing at 1:1.1 with a
2.2% decrease in share price. Furthermore, Humana announced a significant
CFO transition as Susan Diamond decided to step down, causing another jolt in the organization. More trouble for the healthcare giant came from Puerto Rico, with their units facing a
rating downgrade following significant Medicare Advantage losses. This, allied to a decrease in 2025 membership for their top-rated Medicare plans, has added to investor concern. However, in mitigation, Humana has managed to
beat estimates due to its strength in Medicare and primary care. Despite a plunge in ratings recently identified as a
red flag for long-term investors, Humana's stocks are still seen as a worthwhile investment by some analysts and it continues to pay its dividend of $0.885.
Humana HUM News Analytics from Wed, 31 Jul 2024 07:00:00 GMT to Sat, 14 Dec 2024 12:11:55 GMT -
Rating -3
- Innovation -4
- Information -1
- Rumor -2
